Silarsil 140 mg (30 capsules) shining.

SILARSIL (SILARSIL) World Medicine, England TRADE NAME Silarsil, Silarsil INTERNATIONAL UNLICENSED NAME Silymarinum, Silymarin DOSAGE FORM Solid gelatin capsules. Description: Silarsil of 70 mg: the solid gelatin capsule with a lid and the body of opaque dark yellow color containing powder of light brown color. Silarsil of 140 mg: the solid gelatin capsule with a lid of opaque orange color, the body of opaque blue color containing powder of light brown color. STRUCTURE Silarsil of 70 mg: Each capsule contains Active agent: Silymarinum of 70 mg. Excipients: lactoses monohydrate, magnesium stearate. Silarsil of 140 mg: Each capsule contains Active agent: Silymarinum of 140 mg. Excipients: lactoses monohydrate, magnesium stearate. The CODE of DRUG ON automatic telephone exchange of A05BA03 PHARMACOTHERAPEUTIC GROUP Hepatoprotective drugs. PHARMACOLOGICAL Silarsil PROPERTIES - a gepatoprotektor of plant origin which properties are caused by existence in its composition of Silymarinum which represents mix of the extractive substances emitted from fruits of a thistle spotty namely: Silibininum, silidianin, silikristin and other derivatives of a flavonol. Silarsil interacts with free radicals in a liver and transfers them to less toxic connections, interrupting process of peroxide oxidation of lipids, prevents further destruction of cellular structures, interferes with penetration of toxins into liver cells. In the injured hepatocytes under the influence of drug there is a stimulation of synthesis of structural and functional proteins and phospholipids (due to specific stimulation of a RNA polymerase A), stabilization of cellular membranes, prevention of loss of enzymatic components of a cell (transaminase), accelerates regeneration of cells of a liver. Clinically these effects are expressed in improvement of subjective and objective symptomatology, normalization of indicators of a functional condition of a liver (level of transaminases, gamma-globulin, bilirubin). It leads to improvement of the general state, reduction of the complaints connected with digestion, and at patients with bad digestion of food owing to a disease of a liver leads to improvement of appetite. As a result of use of Silymarinum the state after the postponed acute hepatitis improves and in chronic hepatitis (at use as a part of complex therapy). The pharmacokinetics Silibininum (main component of Silymarinum) is soaked up in a digestive tract for 20-40%, the maximum concentration in blood plasma is reached in 0.5-1 h after intake. Т½ makes 6 hours. More than 80% of the entered Silibininum are removed with bile in the form of sulphatic and glyukuronidny conjugates (the last is probably exposed to enterohepatic circulation) and only 3-7% of the entered Silibininum are removed with urine during 24 h. Indications - damage of a liver in alcoholism, - chronic intoxications of a liver (including professional) the halogenated hydrocarbons, compounds of heavy metals and their prevention, - medicinal damages of a liver (in particular, some psychotropic drugs, tuberkulostatika, oral contraceptives, paracetamol, some antibiotics and immunodepressants, anesthetics) and their prevention, - chronic hepatitis of not virus etiology, - cirrhosis (as a part of complex therapy), - a state after infectious and toxic hepatitis, - dystrophy and fat infiltration of a liver, - maintenance therapy in chronic inflammatory diseases of a liver and cirrhosis, - correction of disturbances of lipidic exchange. CONTRAINDICATIONS - hypersensitivity to drug components. SIDE EFFECT from digestive system: seldom - dyspepsia, diarrhea. Dermatological reactions: in some cases - skin manifestations of allergic reactions. Other: in some cases - aggravation of the existing vestibular disturbances. The ROUTE OF ADMINISTRATION AND DOSES use Drug inside after a meal, without chewing, washing down with a small amount of water. Depending on weight zabolevaniyavzroslymnaznachat 70-140 mg 3 times a day. The daily dose can be increased up to 420 mg a day. For maintenance therapy appoint 70-140 mg 2 times a day. The daily dose at children aged from 5 years makes 5 mg/kg of body weight, divided into 2–3 receptions. The course of treatment makes not less than 3 months. OVERDOSE Symptoms: cases of overdose were not observed. Strengthening of severity of side effects is possible. Treatment: in case of reception of a large amount of drug it is necessary to cause vomiting, to wash out a stomach, to appoint activated carbon, symptomatic therapy. INTERACTION WITH OTHER MEDICINES the Data on medicinal interactions are absent. INFLUENCE ON ABILITY to DRIVE the CAR AND OTHER MECHANISMS Is not present the data on an adverse effect of drug on ability to driving by the car and to performance of work demanding the high speed of psychomotor reactions. USE AT PREGNANCY AND the LACTATION At pregnancy and in the period of a lactation drug appoint only according to strict indications and after careful assessment of a ratio advantage/risk. FORM of RELEASE of the Capsule firm gelatinous 70 mg. 10 capsules in the blister. 3 blisters in a cardboard box together with a leaf insert. Capsules firm gelatinous 140 mg. 10 capsules in the blister. 3 blisters in a cardboard box together with a leaf insert. To Store STORAGE CONDITIONS in the place, dry, inaccessible for children, at a temperature not above 30 °C. The EXPIRATION DATE 3 years of date of production. Not to apply after an expiration date.